-
Sign In
- Sony Biotechnology
- Sony Biotechnology
The isolation and expansion of rare and ultra-rare cell populations are important for advancing cell therapy manufacturing. For example, Foxp3-positive naïve regulatory T cells (nTregs) may account for <1% of cells in a sample containing 1 billion leukocytes, making it extremely challenging to isolate them with high purity.
In this webinar, we will provide data on how the CGX10 Cell Isolation System can sort these ultra-rare nTregs directly from a leukopak. We also will share data on how the CGX10 system can be utilized for isolation of positively transduced T cells expressing a green fluorescent protein (GFP) marker at <97% purity using Purity mode.
Key Learning Objectives:
Cell and gene therapy specialists, scientists, and engineers working in research, process development, or manufacturing for diverse applications, including CAR-Treg and Treg therapy, CAR-T, TIL-based therapy, CAR-NK therapy, immune cell therapy, and stem cell therapy.
Dr. Gogishvili supports customers in developing applications for spectral cell analysis and cell sorting. She received her doctoral degree in cellular immunology at the University of Würzburg, Germany, and in academic research explored the role of immune cell subsets in various disease models. As a senior scientist in the translational field of hematology (University of Würzburg), she identified new biomarkers for cell therapies and developed the CAR-T cell manufacturing processes for multiple hematological malignancies. Dr. Gogishvili has also authored publications in high impact journals.